Millennium Management LLC increased its stake in shares of Neos Therapeutics Inc (NASDAQ:NEOS) by 171.9% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 170,045 shares of the company’s stock after acquiring an additional 107,515 shares during the period. Millennium Management LLC owned 0.57% of Neos Therapeutics worth $1,063,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Proxima Capital Management LLC increased its holdings in shares of Neos Therapeutics by 34.1% during the 2nd quarter. Proxima Capital Management LLC now owns 295,000 shares of the company’s stock valued at $1,844,000 after acquiring an additional 75,000 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Neos Therapeutics by 28.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock valued at $352,000 after acquiring an additional 12,500 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Neos Therapeutics during the 2nd quarter valued at about $469,000. Allianz Asset Management GmbH acquired a new position in shares of Neos Therapeutics during the 1st quarter valued at about $161,000. Finally, Nexthera Capital LP acquired a new position in shares of Neos Therapeutics during the 2nd quarter valued at about $2,369,000. 46.88% of the stock is currently owned by institutional investors and hedge funds.
NEOS has been the topic of a number of research analyst reports. ValuEngine raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Wells Fargo & Co lowered their target price on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, August 9th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 target price on shares of Neos Therapeutics in a report on Wednesday, August 8th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $15.50.
NEOS opened at $2.87 on Monday. The company has a market capitalization of $85.16 million, a price-to-earnings ratio of -1.07 and a beta of 0.44. Neos Therapeutics Inc has a 12-month low of $2.84 and a 12-month high of $13.15.
Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.08). The business had revenue of $11.36 million during the quarter, compared to analyst estimates of $11.90 million. Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%. Equities research analysts forecast that Neos Therapeutics Inc will post -1.75 earnings per share for the current fiscal year.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Read More: Understanding Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.